JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2002; 39:1615-1622
© 2002 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zugck, C.
Right arrow Articles by Haass, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zugck, C.
Right arrow Articles by Haass, M.

Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure

Christian Zugck, MD*, Armin Haunstetter, MD*, Carsten Krüger, MD*, Robert Kell, MD*, Dieter Schellberg, MS*, Wolfgang Kübler, MD, FRCP* and Markus Haass, MD*,*

* Department of Cardiology, University of Heidelberg, Heidelberg, Germany



View larger version (14K):

[in a new window]
  		Figure 1 Kaplan-Meier analysis of the 12-month, event-free survival rates of 165 patients with congestive heart failure treated with beta-blockers and 243 patients without beta-blocker treatment.

 


View larger version (24K):

[in a new window]
  		Figure 2 Frequency of combined end points within 12 months in congestive heart failure patients with (black bars) and without (white bars) beta-blocker treatment, stratified by frequently applied cut-off values for peak oxygen consumption (peakVO2) and left ventricular ejection fraction (LVEF) or by tertiles of norepinephrine and N-terminal pro-brain natriuretic peptide (NT-proBNP) (all p < 0.05).

 


View larger version (28K):

[in a new window]
  		Figure 3 Kaplan-Meier analyses of patients with congestive heart failure treated with or without beta-blockers, stratified by (A) peak oxygen consumption (peakVO2) (> or ≤14 ml/min per kg), (B) left ventricular ejection fraction (LVEF) (> or ≤20%) and the median values of (C) norepinephrine and (D) N-terminal pro-brain natriuretic peptide (NT-proBNP) (all p < 0.0001).

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2002 by the American College of Cardiology Foundation.